<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DAPTOMYCIN</span><br/>(dap-to-my'sin)<br/><span class="topboxtradename">Cubicin<br/></span><b>Classifications:</b> <span class="classification">anti-infective</span>; <span class="classification">antibiotic</span>; <span class="classification">lipopeptide</span><br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg vial</p>
<h1><a name="action">Actions</a></h1>
<p>Daptomycin is cyclic lipopeptide antibiotic. It binds to bacterial membranes of gram-positive bacteria causing rapid depolarization
         of the membrane potential leading to inhibition of protein, DNA, and RNA synthesis and bacterial cell death. Lipopeptides
         are bactericidal against gram-positive bacteria.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Daptomycin is effective against a broad spectrum of gram-positive organisms, including both susceptible and resistant strains
         of <i>S. aureus.</i>
</p>
<h1><a name="uses">Uses</a></h1>
<p>Complicated skin and skin structure infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>GI disease, pseudomembranous colitis; myopathy, peripheral neuropathy; rhabdomyolysis; infants, children, elderly, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Severe renal or hepatic impairment, end-stage renal impairment; pregnancy (category B).</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Skin Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 4 mg/kg q24h <small>x</small> 714 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype"> IV Infusion:</span>  Reconstitute the 250 mg vial or the 500 mg vial with 5 mL or 10 mL, respectively, of NS to yield 50 mg/mL. Further dilute
                  the 50 mg/mL solution in 50-100 mL of NS or RL.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> IV Infusion:</span>  Infuse over 30 min; if same IV line is used for infusion of other drugs, flush line before/after with NS or RL.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype"> Solution/additive:</span> Little data available, thus additives or other medications should not be added or infused simultaneously through the same
                  intravenous line. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unopened vials in 2°8° C (36°46° F). Avoid excessive heat. May store reconstituted,
            single-use vials or IV solution for 12 h at room temperature or 48 h if refrigerated. 
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Injection site reactions, fever, fungal infections. <span class="typehead"> CNS:</span> Headache, insomnia, dizziness. <span class="typehead">CV:</span> Hypotension, hypertension. <span class="typehead">GI:</span> Constipation, nausea, vomiting, diarrhea, abnormal liver function tests. <span class="typehead">Hematologic:</span> Anemia. <span class="typehead">Metabolic:</span> Elevated CPK. <span class="typehead">Musculoskeletal:</span> Limb pain, arthralgia. <span class="typehead">Respiratory:</span> Dyspnea. <span class="typehead"> Skin:</span>  Rash, pruritus. <span class="typehead">Urogenital:</span> UTIs, renal failure. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Potential increased risk of myopathy with <span class="classification">statins</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Metabolism:</span> Site of metabolism not determined. <span class="typehead">Elimination:</span> Primarily renal. <span class="typehead">Half-Life:</span> 8 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for and report: muscle pain or weakness, especially with concurrent therapy with HMG-CoA reductase inhibitors (statin
            drugs); S&amp;S of peripheral neuropathy, superinfection such as candidiasis.
         </li>
<li>Lab tests: Perform C&amp;S before treatment is begun; baseline renal function tests; weekly CPK levels; PT/INR during first few
            days of daptomycin therapy with concurrent warfarin use; daily blood glucose monitoring in diabetics; serum electrolytes if
            S&amp;S of hypokalemia or hypomagnesemia (see Appendix F) appear.
         </li>
<li>Withhold drug and notify physician if S&amp;S of myopathy develop with CPK elevation &gt;1000 U/L (<img src="../images/special/approx.gif"/>5
            <small>x</small> ULN), or if CPK level is <img src="../images/special/greaterorequal.gif"/>10 <small>x</small> ULN.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report any of the following to the physician: muscle pain, weakness or unusual tiredness; numbness or tingling; difficulty
            breathing or shortness of breath; severe diarrhea or vomiting; skin rash or itching.
         </li>
<li>Do not breast feed without consulting the physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>